MedTrace Logo

Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

NCT00876317 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2012-07-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety two oral doses of etoricoxib (60 mg and 90 mg) daily in acute soft tissue rheumatism affecting the shoulder.

Conditions

  • Soft Tissue Injuries of the Shoulder
  • Tenosynovitis and Bursitis Affecting the Shoulder

Interventions

DRUG

Etoricoxib 60 mg

Etoricoxib 60 mg per oz per day for 14 days

DRUG

Etoricoxib 90 mg

Etoricoxib 90 mg per oz for 14 days

Sponsors & Collaborators

Principal Investigators

  • Luis F Vidal, MD · Centro Diagnóstico de la Osteoporosis y Enfermedades Reumáticas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • Peru

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00876317 on ClinicalTrials.gov